Theodorus III
VC Fund
Theodorus III is a VC fund focused on Health Care and Biotechnology. Theodorus is the spin-off fund of Université Libre de Bruxelles that invests ininvest in early stage projects based on proprietary disruptive technologies.
- Total investments:
- 22
- Last investment:
- Lead investor:
- 18%
Last updated:
For AI agents: llms.txt
Industries Theodorus III invests in
Stages Theodorus III invests in
Countries Theodorus III invests in
Round sizes
Round size
- Seed
- $67k–$18M
- Series A
- $1.3M–$41M
- Venture - Series Unknown
- $3.6M–$20M
Investment Focus
Industry
- Health Care 9 (41%)
- Biotechnology 6 (27%)
- Software 5 (23%)
- Life Science 5 (23%)
- Medical Device 4 (18%)
Stage
- Series A 7 (32%)
- Seed 6 (27%)
- Venture - Series Unknown 5 (23%)
- Funding Round 2 (9%)
- Pre-Seed 1 (5%)
Country
- Belgium 10 (45%)
- Canada 7 (32%)
- France 2 (9%)
- United States 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Icentia provides a range of innovative medical tests for healthcare institutions. They are able to offer valuable solutions for major problems in the field of medical testing. | Venture - Series Unknown / Aug 18, 2026 | ||
| Ability biologics develops novel, tailored immune modifying biotherapeutics to address unmet medical requirements in cancer and autoimmune disease patients. | $18M / Seed / Jun 18, 2024 | ||
| Simmunome is an artificial intelligence-based contract research organization. They develop industry-ready computational models of pathogenesis and immunogenesis of various diseases with a particular focus on oncology and the nervous system. Our models are achieved by annotating cellular interactions at an in-depth, comprehensive molecular level toattain physiological accuracy | $1.5M / Pre-Seed / Sep 18, 2023 | ||
| We enable companies to prevent cyber attacks before they become costly data breaches. | $2.2M / Series A / Nov 30, 2022 | ||
| Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identifyorthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs. | $41.1M / Series A / May 10, 2022 | ||
| DrugBank augments human intelligence to improve the world’s health. Our suite of products are powered by the world’s most complete and up-to-date pharmaceutical knowledge database. It includes everything there is to know about drugs and how they work in the body. We enable companies to improve healthcare delivery through precision medicine orclinical software applications, as well as uncover insights through data science in drug discovery. Our knowledge base can be integrated into software solutions to help achieve clinical intelligence. Companies can easily scale their usage through our API and launch faster with flexible data modules. By providing users with advanced insights and the right information at the right time, users are empowered to make better health decisions.Our extensive, structured datasets are used to discover novel drug candidates, identify drug repurposing opportunities, and build predictive machine learning models. Companies working with data science can find answers quickly and get drugs to market faster with our evidence-based drug information. Lastly, our publicly available resource, DrugBank Online, is free-to-use with limited datasets available for download for academic and non-commercial researchers. DrugBank has been cited in over 13,000 academic publications and is used by millions of researchers and health professionals globally. | $7.1M / Seed / Apr 11, 2022 | ||
| Contributes to better healthcare thanks to its platform allowing access to structured, validated and anonymised Real World Data. | $3.7M / Seed / Mar 25, 2022 | ||
| HypnoVR is a virtual reality software for anesthesia, treatment of pain, and anxiety. It was founded in 2016 and is based in Strasbourg, France. | $5.1M / Series A / Dec 07, 2021 | ||
| Kaspard is a non-intrusive system that provides more security to residents while respecting their privacy. | $3.7M / Series A / Jul 15, 2021 | ||
| Giiant is a preclinical-stage biotech company that, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerabilityand enhanced therapeutic effect. | $12.4M / Seed / May 21, 2021 | ||
| See all 22 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Theodorus III invest in?
Theodorus III invests primarily in Health Care, Biotechnology and Software startups, most often at Series A and Seed stage. Most of the 22 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Theodorus III's check size?
Theodorus III typically joins rounds of $67k–$18M at Seed, $1.3M–$41M at Series A and $3.6M–$20M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Theodorus III participates in.
When did Theodorus III last invest?
The most recent investment recorded for Theodorus III closed in Aug 2026. Shizune tracks 22 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
